7th Dec 2021 15:11
Okyo Pharma Ltd - London-headquartered biotechnology company - Anticipates filing an investigational new drug application in the third quarter of 2022 for OK-101. The drug is for the treatment of dry eye disease. Expects to start human studies with a phase 2 clinical trial in patients with dry eye disease in the fourth quarter of 2022. Says study is in conjunction with, and will be managed and monitored by, Ora Inc.
"We recognize that news-flow from the company has been limited over the past nine months; however in that time we have been focused on advancing all necessary investigational new drug-enabling studies on OK-101 and are now in a position to announce that we plan to file the investigational new drug applictaion to treat dry eye diease in the third quarter 2022," says Chief Executive Gary Jacob OKYO.
Current stock price: 8.69 pence, up 8.6% on Tuesday
Year-to-date change: up 16%
By Abby Amoakuh; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
OKYO.L